FGI-106 tetrahydrochloride|cas:1149348-10-6|西域试剂

FGI-106 tetrahydrochloride,99.46%

产品编号：Bellancom-124618A| CAS NO：1149348-10-6| 分子式：C₂₈H₄₂Cl₄N₆| 分子量：604.49

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-124618A	￥3500.00	杭州北京（现货）
Bellancom-124618A	￥5500.00	杭州北京（现货）
Bellancom-124618A	￥15000.00	杭州北京（现货）
Bellancom-124618A	￥22000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

FGI-106 tetrahydrochloride

产品介绍

FGI-106 tetrahydrochloride 是一种有效的广谱抑制剂，对多种病毒具有抑制活性。FGI-106 tetrahydrochloride 具有抗埃博拉病毒 (EBOV)，裂谷病毒 (Rift Valley virus) 和登革热病毒 (Dengue Fever virus) 的活性，其 EC₅₀ 分别为 100 nM，800 nM 和 400-900 nM。FGI-106 tetrahydrochloride 还分别以 EC₅₀ 值为 200 nM 和 150 nM 抑制非失血性发热病毒 HCV 和 HIV-1。

生物活性

FGI-106 tetrahydrochloride is a potent and broad-spectrum inhibitor with inhibitory activity against multiple viruses. FGI-106 tetrahydrochloride is active against Ebola, Rift Valley and Dengue Fever viruses with EC₅₀s of 100 nM, 800 nM and 400-900 nM, respectively. FGI-106 tetrahydrochloride also inhibits non-hemorrhagic fever viruses HCV and HIV-1 with EC₅₀s of 200 nM and 150 nM, respectively.

体外研究

Treatment with 2 μM FGI-106 mediated a 4 log reduction in infectious viral titers relative to matched controls, with an EC₉₀ for inhibition of viral killing of host cells (Vero E6 cells) estimated to be 0.6 μM.
In cell-based assays, treatment with FGI-106 inhibits viral replication by divergent virus families, including positive and negative-strand RNA viruses.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

FGI-106 (0.1-5 mg/kg; intraperitoneal injection; treatments on days 2 and 5; C57BL/6 or BALB/c mice) treatment decreases mortality from Zaire EBOV in a dose-dependent manner.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male or female C57BL/6 or BALB/c mice (6-10 weeks of age) injected with EBOV (Ebola virus)
Dosage:	0.1 mg/kg, 0.5 mg/kg, 1 mg/kg, 2 mg/kg, 5 mg/kg
Administration:	Intraperitoneal injection; treatments on days 2 and 5
Result:	Decreased mortality from Zaire EBOV in a dose-dependent manner.

体内研究

FGI-106 (0.1-5 mg/kg; intraperitoneal injection; treatments on days 2 and 5; C57BL/6 or BALB/c mice) treatment decreases mortality from Zaire EBOV in a dose-dependent manner.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male or female C57BL/6 or BALB/c mice (6-10 weeks of age) injected with EBOV (Ebola virus)
Dosage:	0.1 mg/kg, 0.5 mg/kg, 1 mg/kg, 2 mg/kg, 5 mg/kg
Administration:	Intraperitoneal injection; treatments on days 2 and 5
Result:	Decreased mortality from Zaire EBOV in a dose-dependent manner.

性状

Solid

溶解性数据

In Vitro:

DMSO : 6.67 mg/mL (11.03 mM; ultrasonic and warming and adjust pH to 2 with HCl and heat to 60°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.6543 mL	8.2714 mL	16.5429 mL
5 mM	0.3309 mL	1.6543 mL	3.3086 mL
10 mM	0.1654 mL	0.8271 mL	1.6543 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 0.67 mg/mL (1.11 mM); Clear solution

此方案可获得 ≥ 0.67 mg/mL (1.11 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 6.7 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 0.67 mg/mL (1.11 mM); Clear solution

此方案可获得 ≥ 0.67 mg/mL (1.11 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 6.7 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明